These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 23699656)

  • 1. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
    Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D
    Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.
    Ji J; Yu Y; Li ZL; Chen MY; Deng R; Huang X; Wang GF; Zhang MX; Yang Q; Ravichandran S; Feng GK; Xu XL; Yang CL; Qiu MZ; Jiao L; Yang D; Zhu XF
    Theranostics; 2018; 8(6):1494-1510. PubMed ID: 29556337
    [No Abstract]   [Full Text] [Related]  

  • 3. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis.
    Li N; Feng L; Han HQ; Yuan J; Qi XK; Lian YF; Kuang BH; Zhang YC; Deng CC; Zhang HJ; Yao YY; Xu M; He GP; Zhao BC; Gao L; Feng QS; Chen LZ; Yang L; Yang D; Zeng YX
    Cancer Lett; 2016 Oct; 381(1):14-22. PubMed ID: 27424523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.
    Lu J; McEachern D; Sun H; Bai L; Peng Y; Qiu S; Miller R; Liao J; Yi H; Liu M; Bellail A; Hao C; Sun SY; Ting AT; Wang S
    Mol Cancer Ther; 2011 May; 10(5):902-14. PubMed ID: 21372226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
    Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
    BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
    Bockbrader KM; Tan M; Sun Y
    Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity.
    Sun H; Liu L; Lu J; Bai L; Li X; Nikolovska-Coleska Z; McEachern D; Yang CY; Qiu S; Yi H; Sun D; Wang S
    J Med Chem; 2011 May; 54(9):3306-18. PubMed ID: 21462933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.
    Lecis D; Drago C; Manzoni L; Seneci P; Scolastico C; Mastrangelo E; Bolognesi M; Anichini A; Kashkar H; Walczak H; Delia D
    Br J Cancer; 2010 Jun; 102(12):1707-16. PubMed ID: 20461078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smac mimetics can provoke lytic cell death that is neither apoptotic nor necroptotic.
    Miles MA; Caruso S; Baxter AA; Poon IKH; Hawkins CJ
    Apoptosis; 2020 Aug; 25(7-8):500-518. PubMed ID: 32440848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
    Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
    Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα.
    Shekhar TM; Miles MA; Gupte A; Taylor S; Tascone B; Walkley CR; Hawkins CJ
    Oncotarget; 2016 Jun; 7(23):33866-86. PubMed ID: 27129149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.
    Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L
    BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
    Welsh K; Milutinovic S; Ardecky RJ; Gonzalez-Lopez M; Ganji SR; Teriete P; Finlay D; Riedl S; Matsuzawa S; Pinilla C; Houghten R; Vuori K; Reed JC; Cosford ND
    PLoS One; 2016; 11(9):e0161952. PubMed ID: 27617834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics.
    Lee EW; Seong D; Seo J; Jeong M; Lee HK; Song J
    Cell Death Differ; 2015 Sep; 22(9):1463-76. PubMed ID: 25613375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs.
    Finlay D; Vamos M; González-López M; Ardecky RJ; Ganji SR; Yuan H; Su Y; Cooley TR; Hauser CT; Welsh K; Reed JC; Cosford ND; Vuori K
    Mol Cancer Ther; 2014 Jan; 13(1):5-15. PubMed ID: 24194568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.
    Metwalli AR; Khanbolooki S; Jinesh G; Sundi D; Shah JB; Shrader M; Choi W; Lashinger LM; Chunduru S; McConkey DJ; McKinlay M; Kamat AM
    Cancer Biol Ther; 2010 Nov; 10(9):885-92. PubMed ID: 20814238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.
    Langdon CG; Wiedemann N; Held MA; Mamillapalli R; Iyidogan P; Theodosakis N; Platt JT; Levy F; Vuagniaux G; Wang S; Bosenberg MW; Stern DF
    Oncotarget; 2015 Nov; 6(35):37410-25. PubMed ID: 26485762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.
    Servida F; Lecis D; Scavullo C; Drago C; Seneci P; Carlo-Stella C; Manzoni L; Polli E; Lambertenghi Deliliers G; Delia D; Onida F
    Invest New Drugs; 2011 Dec; 29(6):1264-75. PubMed ID: 20614162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.
    Bai L; McEachern D; Yang CY; Lu J; Sun H; Wang S
    Cancer Res; 2012 Mar; 72(5):1229-38. PubMed ID: 22241084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.